NCT00480987: Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) |
|
|
| Terminated | 1/2 | 27 | US | Oxaliplatin, Eloxatin®, Fludarabine, Fludara®, Fludarabine Phosphate, Cytarabine, Ara-C | M.D. Anderson Cancer Center, Sanofi | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia | 08/10 | 08/10 | | |
NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
|
|
| Active, not recruiting | 1/2 | 90 | US | galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, Pembrolizumab, MK-3475, Keytruda | Sellas Life Sciences Group, Merck Sharp & Dohme LLC, Cancer Insight, LLC | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | 11/22 | 04/23 | | |
